GlassScriptPhysician profile
Kenneth T Smith
NPI 1396851689
$1,020.75
in general payments reported to CMS, 2019-2025
18 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $198 · 2022: $195 · 2023: $176 · 2024: $108 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $155.54 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $132.64 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $124.32 | 2021-2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $86.92 | 2021-2023 | Belsomra, Verquvo, Steglatro |
| Otsuka America Pharmaceutical, INC. | $83.35 | 2024-2025 | Rexulti |
| Abbvie INC. | $81.79 | 2022-2024 | |
| Corcept Therapeutics | $71.35 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $64.34 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $43.16 | 2025 | |
| Electromed, INC. | $39.03 | 2021-2025 | Smartvest |
| Biohaven Pharmaceuticals, INC. | $21.69 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.01 | 2025 | Caplyta |
| Grifols USA, LLC | $18.70 | 2024 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $17.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.86 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $16.50 | 2021 | |
| Axsome Therapeutics, INC. | $13.56 | 2023 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.